Apyx Medical Corp Q4 Revenue Up 34.7% YoY, FY26 Revenue View Raised 9%-10%, Stock Jumps 2.29%

Apyx Medical Corp reported a narrower net loss in Q4 and FY25 due to revenue growth, driven by a 36% increase in surgical aesthetics sales. The firm raised its FY26 revenue view by 9%-10% and expects total revenue in the range of $57.5-$58.5 million. Surgical aesthetics revenue is expected to be $53.0-$54.0 million, while OEM revenue is expected to be approximately $4.5 million. The company had cash and cash equivalents of $31.74 million as of December 31, 2025.